GI Dynamics has introduced EndoBarrier Gastrointestinal Liner from clinical research to commercial use in the Netherlands to treat type 2 diabetes and/or obesity.
The EndoBarrier is a non-surgical device which lowers blood glucose levels and promote weight loss in diabetic and obese patients during the implant period.
The company said nearly 100 patients have been treated with the EndoBarrier in clinical trials conducted in the Netherlands.
The findings from one of the study showed that the EndoBarrier changes certain gastrointestinal hormones involved in insulin sensitivity, glucose metabolism and satiety which allow for rapid and sustained improvement of type 2 diabetes.
GI Dynamics president and CEO Stuart Randle said in particular, the success of Center of Excellence in the Netherlands’ implantion of the EndoBarrier under conscious sedation is very exciting and could potentially translate into reduced costs and even more rapid recovery.
The company said the EndoBarrier has also received TGA approval and will soon be available in Australia.